Ipsen publishes its 2020 Universal Registration Document
Ipsen publishes its 2020 Universal Registration Document
This article or press release has no online content. Please download the associated documents for more information.
Ipsen publishes its 2020 Universal Registration Document
- 15 April 2021 - 1 mins read
This article or press release has no online content. Please download the associated documents for more information.
Related Press Releases
![TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
19 January 2024
7 mins read
TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA
![IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
14 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
![Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
13 November 2023
11 mins read
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...
![IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
07 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
![Ipsen updates on QM-1114 regulatory process Ipsen updates on QM-1114 regulatory process](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
03 October 2023
5 mins read
Ipsen updates on QM-1114 regulatory process
![IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
26 September 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
![Ipsen nominates Pascal Touchon to its Board of Directors as new independent director Ipsen nominates Pascal Touchon to its Board of Directors as new independent director](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
04 September 2023
5 mins read
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
![Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
21 August 2023
15 mins read
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
![IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
18 July 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023
![Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
01 June 2023
2 mins read